Intelligent Bio Solutions Scales Production with Syrma Johari, Eyes U.S. Expansion

Event summary

  • Intelligent Bio Solutions shipped first batch of readers from new manufacturing partner Syrma Johari, validating 4x production capacity increase.
  • Partnership expected to deliver >40% annual production cost savings, boosting gross margins by ~20 percentage points.
  • Company doubled in-house lateral flow test strip production, enabling faster R&D and expanded drug panel capabilities.
  • Readers deployed across U.K. and Europe ahead of planned 2026 U.S. market entry beyond forensic use.
  • Manufacturing meets ISO 13485 and MDSAP regulatory standards.

The big picture

This manufacturing scale-up positions Intelligent Bio Solutions to compete more aggressively in the growing workplace drug testing market, particularly as safety-critical industries increasingly adopt rapid, non-invasive testing solutions. The vertical integration strategy aligns with broader industry trends toward cost-efficient, high-margin diagnostic platforms. Success will depend on maintaining operational momentum while navigating U.S. regulatory hurdles.

What we're watching

Margin Expansion
Whether the 20-point gross margin improvement can be sustained as U.S. market entry ramps up.
Execution Risk
The pace at which the company can scale production while maintaining quality standards.
Market Timing
How U.S. regulatory approvals will impact the planned 2026 market entry beyond forensic use.

Related topics

Diagnostics